Working… Menu

Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia (V-FIRST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03455504
Recruitment Status : Unknown
Verified October 2018 by Gruppo Italiano Malattie EMatologiche dell'Adulto.
Recruitment status was:  Not yet recruiting
First Posted : March 6, 2018
Last Update Posted : October 15, 2018
Information provided by (Responsible Party):
Gruppo Italiano Malattie EMatologiche dell'Adulto

Brief Summary:
This study will test the effectiveness and safety of Venetoclax in combination with standard induction regimen for patients with acute leukemia and poor prognosis.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Venetoclax Phase 2

Detailed Description:

Intensive treatment of Acute Leukemia, multidrug based chemotherapy induction, achieves complete remission (CR) rates ranging from 50% to 80%. Nonetheless, the majority (60- 70%) of responding patients will eventually relapse.

Patients with non-low risk leukemia according most diffuse risk scores have a poor prognosis and a short survival. For these patient traditional chemotherapy seems to be ineffective, even with BMT consolidation, probably due to activation of survival pathways in Leukemia cells, so that novel therapeutic interventions should be attempted.

This study will test the effectiveness and safety of Venetoclax, a selective BCL2 inhibitor, in combination with standard induction regimen.

Inhibiting anti-apoptotic pathway of BCL2, the investigators expect to improve success rate of standard chemotherapies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 124 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Study run-in and phase II
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Study Investigating Safety, Tolerability and Effectiveness of Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction of New Onset Non-M3 Acute Myelid Leukemia
Estimated Study Start Date : December 2018
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : September 2020

Arm Intervention/treatment
Experimental: Cohort 1
FLAI + V400 mg
Drug: Venetoclax
Venetoclax add in combination with fludarabine, cyratabine and idarubicine

Experimental: Cohort 2
FLAI + V600 mg
Drug: Venetoclax
Venetoclax add in combination with fludarabine, cyratabine and idarubicine

Primary Outcome Measures :
  1. Number of patients achieving complete response (CR) after course 1 or course 2 if course 2 is administered (CR + CRi + CRp) [ Time Frame: At 24 months from study entry ]
    Efficacy in new onset, non ELN Low risk AML (safety run-in, part1, and part2). Effectiveness of Venetoclax added in combination with chemotherapy in obtaining Complete remission in new onset, non ELN Low risk AML (safety run-in, part1, and part2).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with documented/confirmed new onset non-m3 acute myeloid leukemia, according to WHO 2017 will be eligible for this study.
  • Hematological illness has to be graded intermediate or high risk according ELN criteria
  • Patients ≥ 18 years old and ≤ 65 years old
  • ECOG performance status ≤ 2.
  • Patients with a life expectancy >12 weeks
  • Patients may have AML which has arisen from prior therapies or other antecedent disorder
  • Adequate hepatic function
  • Adequate pancreatic function
  • Adequate renal function assessed by: Serum creatinine within reference laboratory ranges or creatinine clearance (by Cockcroft Gault formula, see Appendix 2) ≥ 50 mL/min for patients in whom, in the Investigator's judgment, serum creatinine level may not adequately reflect renal function.
  • All non-hematological adverse events must have resolved to NCI-CTCAE Grade ≤ 2 prior to starting therapy.
  • Patients must be considered by Investigator suitable to receive combination chemotherapy.
  • Combination chemotherapy has not to be considered toxic without expectation of any benefit for the patient
  • For females of childbearing potential, a negative pregnancy test must be documented within 72 hours prior to the first study drug administration.
  • All patients must be willing to use effective methods of contraception, during the treatment period and for 100 days after the last dose of Venetoclax. Female patients must be postmenopausal (≥ 1 year of amenorrhea), surgically sterile, or they must agree to use 2 adequate methods of contraception with at least one method with a failure rate of

    ≤ 1% per year (e.g., hormonal implants, combined oral contraceptives, vasectomized partner) and the second preferably a physical barrier method of contraception. Oral or injectable contraceptive agents cannot be the sole method of contraception. Male patients must be surgically sterile or agree to use an acceptable method of contraception.

  • Patient must be willing to submit the blood sampling and bone marrow sampling for the PK and PD analyses and exploratory biomarkers.
  • Ability to understand and willingness to sign an informed consent form.
  • Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria:

  • Patients with low risk AML according ELN criteria
  • Patients with current clinical evidence of CNS leukemia.
  • Patients receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy with the exception of Hydroxyurea (HU) or 6-Mercaptopurine (6MP) in patients who need to continue this agent to maintain WBC count ≤10,000/mm3. HU and 6MP must be discontinued at the time of initiation of study medications.
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study including but not limited at:
  • unstable angina
  • Patients who are on anti-microbial agents with therapeutic intent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03455504

Layout table for location contacts
Contact: Enrico Crea +39 0670390514
Contact: Paola Fazi +39 0670390514

Layout table for location information
Ematologia - ASST Papa Giovanni XXIII
Bergamo, Italy
Contact: Alessandro Rambaldi         
Principal Investigator: Alessandro Rambaldi         
Spedali Civili - Azienda Ospedaliera U.O. Ematologia
Brescia, Italy
Contact: Giuseppe Rossi         
Principal Investigator: Giuseppe Rossi         
Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto"
Catania, Italy
Contact: Francesco Di Raimondo         
Principal Investigator: Francesco Di Raimondo         
A.O.U. Careggi - Ematologia
Firenze, Italy
Contact: Alberto Bosi         
Principal Investigator: Alberto Bosi         
Istituto Scientifico Romagnoli per lo Studio e la Cura dei Tumori IRST
Meldola, Italy
Contact: Giovanni Martinelli         
Principal Investigator: Giovanni Martinelli         
Ospedale Niguarda "Ca Granda" SC Ematologia
Milano, Italy
Contact: Roberto Cairoli         
Principal Investigator: Roberto Cairoli         
U.O. Ematologia e Trapianto di Midollo Ist. Scientifico Ospedale San Raffaele
Milano, Italy
Contact: Fabio Ciceri         
Principal Investigator: Fabio Ciceri         
U.O.C. Ematologia e CTMO Az Ospedaliero Universitaria
Parma, Italy
Contact: Giovanni Roti         
Principal Investigator: Giovanni Roti         
Dipartimento Oncologico - Ospedale S. Maria delle Croci
Ravenna, Italy
Contact: Francesco Lanza         
Principal Investigator: Francesco Lanza         
Università degli Studi "Sapienza" Dip. Biotecnologie Cellulari ed Ematologia
Roma, Italy
Contact: Roberto Foà         
Principal Investigator: Roberto Foà         
Dipartimento di Oncologia ed Ematologia S.C. -Città della Scienza di Torino San Giovanni Battista
Torino, Italy
Contact: Ernesta Audisio         
Principal Investigator: Ernesta Audisio         
Sponsors and Collaborators
Gruppo Italiano Malattie EMatologiche dell'Adulto
Layout table for investigator information
Study Chair: Giovanni Martinelli Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) Meldola
Study Director: Fabio Ciceri Istituto S. Raffaele, Milan
Additional Information:
Layout table for additonal information
Responsible Party: Gruppo Italiano Malattie EMatologiche dell'Adulto Identifier: NCT03455504    
Other Study ID Numbers: AML1718
2018-000392-33 ( EudraCT Number )
First Posted: March 6, 2018    Key Record Dates
Last Update Posted: October 15, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gruppo Italiano Malattie EMatologiche dell'Adulto:
Acute myeloid leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antineoplastic Agents